{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T01:36:57Z","timestamp":1789263417449,"version":"build-2803163510"},"reference-count":83,"publisher":"Bentham Science Publishers Ltd.","issue":"3","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health, USA","doi-asserted-by":"publisher","award":["AI151970"],"award-info":[{"award-number":["AI151970"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["AIA"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>This article reviews preclinical and clinical studies on the repurposed use of disulfiram (Antabuse) as an antimicrobial agent. Preclinical research covered on the alcohol sobriety aid includes uses as an anti-MRSA agent, a carbapenamase inhibitor, antifungal drug for candidiasis, and treatment for parasitic diseases due to protozoa (e.g., giardiasis, leishmaniasis, malaria) and helminthes (e.g., schistosomiasis, trichuriasis). Past, current, and pending clinical studies on di-sulfiram as a post-Lyme disease syndrome (PTLDS) therapy, an HIV latency reversal agent, and intervention for COVID-19 infections are also reviewed.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/2211352520666220104104747","type":"journal-article","created":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T07:58:07Z","timestamp":1641369487000},"update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Disulfiram: A Repurposed Drug in Preclinical and Clinical Development\nfor the Treatment of Infectious Diseases"],"prefix":"10.2174","volume":"20","author":[{"given":"Marco M.","family":"Custodio","sequence":"first","affiliation":[{"name":"Chesapeake Regional Medical Center, 736 Battlefield Blvd. N Chesapeake, VA 23320, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Sparks","sequence":"additional","affiliation":[{"name":"Department of Pharmacy\nPractice, Administration and Research, Marshall University School of Pharmacy, One John Marshall Drive, Huntington\nWV 24755-0001, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0213-4726","authenticated-orcid":true,"given":"Timothy E.","family":"Long","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Science and Research, Marshall University School of Pharmacy,\nOne John Marshall, Drive Huntington WV 24755-0001, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/0002-9343(90)90534-K","volume":"88","author":"Wright C.","year":"1990","unstructured":"Wright C.; Moore R.D.; Disulfiram treatment of alcoholism. Am J Med 1990,88(6),647-655","journal-title":"Am J Med"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1001\/jama.1937.02780340020007","volume":"109","author":"Williams E.E.","year":"1937","unstructured":"Williams E.E.; Effects of alcohol on workers with carbon disulfide. J Am Med Assoc 1937,109,1472-1473","journal-title":"J Am Med Assoc"},{"key":"ref=3","first-page":"82","volume":"33","author":"Kragh H.","year":"2008","unstructured":"Kragh H.; From disulfiram to Antabuse: The invention of a drug. Bull Hist Chem 2008,33,82-88","journal-title":"Bull Hist Chem"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"185","DOI":"10.15288\/qjsa.1949.10.185","volume":"10","author":"Glud E.","year":"1949","unstructured":"Glud E.; The treatment of alcoholic patients in Denmark with antabuse with suggestions for its trial in the United States. Q J Stud Alcohol 1949,10(2),185-197","journal-title":"Q J Stud Alcohol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/dar.12018","volume":"32","author":"Ellis P.M.","year":"2013","unstructured":"Ellis P.M.; Dronsfield A.T.; Antabuse\u2019s diamond anniversary: still sparkling on? Drug Alcohol Rev 2013,32(4),342-344","journal-title":"Drug Alcohol Rev"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1600-0447.1992.tb03310.x","volume":"369","author":"Johansson B.","year":"1992","unstructured":"Johansson B.; A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites. Acta Psychiatr Scand Suppl 1992,369,15-26","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/S0006-2952(00)00435-4","volume":"60","author":"Shen M.L.","year":"2000","unstructured":"Shen M.L.; Lipsky J.J.; Naylor S.; Role of disulfiram in the in vitro inhibition of rat liver mitochondrial aldehyde dehydrogenase. Biochem Pharmacol 2000,60(7),947-953","journal-title":"Biochem Pharmacol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1600-0447.1992.tb03309.x","volume":"369","author":"Petersen E.N.","year":"1992","unstructured":"Petersen E.N.; The pharmacology and toxicology of disulfiram and its metabolites. Acta Psychiatr Scand Suppl 1992,369,7-13","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.drugalcdep.2013.12.007","volume":"136","author":"Schottenfeld R.S.","year":"2014","unstructured":"Schottenfeld R.S.; Chawarski M.C.; Cubells J.F.; George T.P.; Lappalainen J.; Kosten T.R.; Randomized clinical trial of disulfiram for cocaine dependence or abuse during buprenorphine treatment. Drug Alcohol Depend 2014,136,36-42","journal-title":"Drug Alcohol Depend"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1634\/theoncologist.2014-0424","volume":"20","author":"Nechushtan H.","year":"2015","unstructured":"Nechushtan H.; Hamamreh Y.; Nidal S.; Gotfried M.; Baron A.; Shalev Y.I.; Nisman B.; Peretz T.; Peylan-Ramu N.; A phase IIb trial assessing the addition of disulfiram to chemotherapy for the treatment of metastatic non-small cell lung cancer. Oncologist 2015,20(4),366-367","journal-title":"Oncologist"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s11060-019-03125-y","volume":"142","author":"Huang J.","year":"2019","unstructured":"Huang J.; Chaudhary R.; Cohen A.L.; Fink K.; Goldlust S.; Boockvar J.; Chinnaiyan P.; Wan L.; Marcus S.; Campian J.L.; A multi-center phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma. J Neurooncol 2019,142(3),537-544","journal-title":"J Neurooncol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/cpt.1220","volume":"105","author":"Lee S.A.","year":"2019","unstructured":"Lee S.A.; Elliott J.H.; McMahon J.; Hartogenesis W.; Bumpus N.N.; Lifson J.D.; Gorelick R.J.; Bacchetti P.; Deeks S.G.; Lewin S.R.; Savic R.M.; Population pharmacokinetics and pharmacodynamics of disulfiram on inducing latent HIV-1 transcription in a Phase IIb Tri-al. Clin Pharmacol Ther 2019,105(3),692-702","journal-title":"Clin Pharmacol Ther"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1128\/AAC.35.4.785","volume":"35","author":"Phillips M.","year":"1991","unstructured":"Phillips M.; Malloy G.; Nedunchezian D.; Lukrec A.; Howard R.G.; Disulfiram inhibits the in vitro growth of methicillin-resistant staph-ylococcus aureus. Antimicrob Agents Chemother 1991,35(4),785-787","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"e00898","DOI":"10.1128\/AAC.00898-17","volume":"61","author":"Long T.E.","year":"2017","unstructured":"Long T.E.; Repurposing thiram and disulfiram as antibacterial agents for multidrug-resistant Staphylococcus aureus infections. Antimicrob Agents Chemother 2017,61(9),e00898-e17","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.ijantimicag.2019.03.024","volume":"53","author":"Thakare R.","year":"2019","unstructured":"Thakare R.; Shukla M.; Kaul G.; Dasgupta A.; Chopra S.; Repurposing disulfiram for treatment of Staphylococcus aureus infections. Int J Antimicrob Agents 2019,53(6),709-715","journal-title":"Int J Antimicrob Agents"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/jam.14094","volume":"126","author":"Frazier K.R.","year":"2019","unstructured":"Frazier K.R.; Moore J.A.; Long T.E.; Antibacterial activity of disulfiram and its metabolites. J Appl Microbiol 2019,126(1),79-86","journal-title":"J Appl Microbiol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.2174\/092986712800609788","volume":"19","author":"Santos A.L.","year":"2012","unstructured":"Santos A.L.; Sodre C.L.; Valle R.S.; Silva B.A.; Abi-Chacra E.A.; Silva L.V.; Souza-Goncalves A.L.; Sangenito L.S.; Goncalves D.S.; Souza L.O.; Palmeira V.F.; d\u2019Avila-Levy C.M.; Kneipp L.F.; Kellett A.; McCann M.; Branquinha M.H.; Antimicrobial action of chelat-ing agents: repercussions on the microorganism development, virulence and pathogenesis. Curr Med Chem 2012,19(17),2715-2737","journal-title":"Curr Med Chem"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/nrmicro3028","volume":"11","author":"Lemire J.A.","year":"2013","unstructured":"Lemire J.A.; Harrison J.J.; Turner R.J.; Antimicrobial activity of metals: mechanisms, molecular targets and applications. Nat Rev Microbiol 2013,11(6),371-384","journal-title":"Nat Rev Microbiol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1039\/C9SC06460E","volume":"11","author":"Frei A.","year":"2020","unstructured":"Frei A.; Zuegg J.; Elliott A.G.; Baker M.; Braese S.; Brown C.; Chen F.; G. Dowson; C; Dujardin, G; Jung, N; King, AP; Mansour, AM; Massi, M; Moat, J; Mohamed, HA; Renfrew, AK; Rutledge, PJ; Sadler, PJ; Todd, MH; Willans, CE; Wilson, JJ; Cooper, MA; Blaskovich, MAT Metal complexes as a promising source for new antibiotics. Chem Sci (Camb) 2020,11(10),2627-2639","journal-title":"Chem Sci (Camb)"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/bs.ampbs.2017.01.007","volume":"70","author":"Dalecki A.G.","year":"2017","unstructured":"Dalecki A.G.; Crawford C.L.; Wolschendorf F.; Copper and antibiotics: discovery, modes of action, and opportunities for medicinal ap-plications. Adv Microb Physiol 2017,70,193-260","journal-title":"Adv Microb Physiol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1128\/AAC.02316-13","volume":"58","author":"Haeili M.","year":"2014","unstructured":"Haeili M.; Moore C.; Davis C.J.; Cochran J.B.; Shah S.; Shrestha T.B.; Zhang Y.; Bossmann S.H.; Benjamin W.H.; Kutsch O.; Wolschendorf F.; Copper complexation screen reveals compounds with potent antibiotic properties against methicillin-resistant Staphylo-coccus aureus. Antimicrob Agents Chemother 2014,58(7),3727-3736","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=22","first-page":"e01674","volume":"62","author":"Saputo S.","year":"2017","unstructured":"Saputo S.; Faustoferri R.C.; Quivey R.G.; Jr A drug repositioning approach reveals that Streptococcus mutans is susceptible to a diverse range of established antimicrobials and nonantibiotics. Antimicrob Agents Chemother 2017,62(1),e01674-17","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"4835","DOI":"10.1128\/AAC.00692-15","volume":"59","author":"Dalecki A.G.","year":"2015","unstructured":"Dalecki A.G.; Haeili M.; Shah S.; Speer A.; Niederweis M.; Kutsch O.; Wolschendorf F.; Disulfiram and copper ions kill Mycobacte-rium tuberculosis in a synergistic manner. Antimicrob Agents Chemother 2015,59(8),4835-4844","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.3389\/fmicb.2019.01720","volume":"10","author":"Totten A.H.","year":"2019","unstructured":"Totten A.H.; Crawford C.L.; Dalecki A.G.; Xiao L.; Wolschendorf F.; Atkinson T.P.; Differential susceptibility of Mycoplasma and Ureaplasma species to compound-enhanced copper toxicity. Front Microbiol 2019,10,1720","journal-title":"Front Microbiol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/nchembio.559","volume":"7","author":"Ejim L.","year":"2011","unstructured":"Ejim L.; Farha M.A.; Falconer S.B.; Wildenhain J.; Coombes B.K.; Tyers M.; Brown E.D.; Wright G.D.; Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy. Nat Chem Biol 2011,7(6),348-350","journal-title":"Nat Chem Biol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1021\/bi4015852","volume":"53","author":"Thompson M.K.","year":"2014","unstructured":"Thompson M.K.; Keithly M.E.; Goodman M.C.; Hammer N.D.; Cook P.D.; Jagessar K.L.; Harp J.; Skaar E.P.; Armstrong R.N.; Struc-ture and function of the genomically encoded fosfomycin resistance enzyme, FosB, from Staphylococcus aureus. Biochemistry 2014,53(4),755-765","journal-title":"Biochemistry"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ijantimicag.2019.04.002","volume":"54","author":"Hamblin K.A.","year":"2019","unstructured":"Hamblin K.A.; Flick-Smith H.; Barnes K.B.; Pereira-Leal J.B.; Surkont J.; Hampson R.; Atkins H.S.; Harding S.V.; Disulfiram, an alcohol dependence therapy, can inhibit the in vitro growth of Francisella tularensis. Int J Antimicrob Agents 2019,54(1),85-88","journal-title":"Int J Antimicrob Agents"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.2147\/DDDT.S101486","volume":"10","author":"Pothineni V.R.","year":"2016","unstructured":"Pothineni V.R.; Wagh D.; Babar M.M.; Inayathullah M.; Solow-Cordero D.; Kim K.M.; Samineni A.V.; Parekh M.B.; Tayebi L.; Rajadas J.; Identification of new drug candidates against Borrelia burgdorferi using high-throughput screening. Drug Des Devel Ther 2016,10,1307-1322","journal-title":"Drug Des Devel Ther"},{"key":"ref=29","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9090633","volume":"9","author":"Potula H.S.K.","year":"2020","unstructured":"Potula H.S.K.; Shahryari J.; Inayathullah M.; Malkovskiy A.V.; Kim K-M.; Rajadas J.; Repurposing disulfiram (tetraethylthiuram disul-fide) as a potential drug candidate against Borrelia burgdorferi in vitro and in vivo. Antibiotics (Basel) 2020,9(9)","journal-title":"Antibiotics (Basel)"},{"key":"ref=30","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9090542","volume":"9","author":"Alvarez-Manzo H.S.","year":"2020","unstructured":"Alvarez-Manzo H.S.; Zhang Y.; Shi W.; Zhang Y.; Evaluation of disulfiram drug combinations and identification of other more effective combinations against stationary phase Borrelia burgdorferi. Antibiotics (Basel) 2020,9(9)","journal-title":"Antibiotics (Basel)"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.2147\/IDR.S299177","volume":"14","author":"Kobatake T.","year":"2021","unstructured":"Kobatake T.; Ogino K.; Sakae H.; Gotoh K.; Watanabe A.; Matsushita O.; Okada H.; Yokota K.; Antibacterial effects of disulfiram in Helicobacter pylori. Infect Drug Resist 2021,14,1757-1764","journal-title":"Infect Drug Resist"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"6791","DOI":"10.1002\/cam4.3346","volume":"9","author":"Hu H.","year":"2020","unstructured":"Hu H.; Cui L.; Lu J.; Wei K.; Wei J.; Li S.; Zou C.; Chen T.; Intestinal microbiota regulates anti-tumor effect of disulfiram combined with Cu2+ in a mice model. Cancer Med 2020,9(18),6791-6801","journal-title":"Cancer Med"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1039\/C9CC09074F","volume":"56","author":"Chen C.","year":"2020","unstructured":"Chen C.; Yang K.W.; Wu L.Y.; Li J.Q.; Sun L.Y.; Disulfiram as a potent metallo-\u03b2-lactamase inhibitor with dual functional mechanisms. Chem Commun (Camb) 2020,56(18),2755-2758","journal-title":"Chem Commun (Camb)"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"6288","DOI":"10.1128\/AAC.00883-15","volume":"59","author":"Caskey J.R.","year":"2015","unstructured":"Caskey J.R.; Embers M.E.; Persister development by Borrelia burgdorferi populations in vitro. Antimicrob Agents Chemother 2015,59(10),6288-6295","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=35","unstructured":"U.S. National Institutes of Health ClinicalTrials Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03891667"},{"key":"ref=36","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics8020072","volume":"8","author":"Liegner K.B.","year":"2019","unstructured":"Liegner K.B.; Disulfiram (tetraethylthiuram disulfide) in the treatment of Lyme disease and babesiosis: report of experience in three cases. Antibiotics (Basel) 2019,8(2)","journal-title":"Antibiotics (Basel)"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3389\/fmed.2020.00133","volume":"7","author":"Trautmann A.","year":"2020","unstructured":"Trautmann A.; Gascan H.; Ghozzi R.; Potential patient-reported toxicities with disulfiram treatment in late disseminated Lyme disease. Front Med (Lausanne) 2020,7,133","journal-title":"Front Med (Lausanne)"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"4140","DOI":"10.1128\/AAC.06445-11","volume":"56","author":"Horita Y.","year":"2012","unstructured":"Horita Y.; Takii T.; Yagi T.; Ogawa K.; Fujiwara N.; Inagaki E.; Kremer L.; Sato Y.; Kuroishi R.; Lee Y.; Makino T.; Mizukami H.; Hasegawa T.; Yamamoto R.; Onozaki K.; Antitubercular activity of disulfiram, an antialcoholism drug, against multidrug- and extensive-ly drug-resistant Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 2012,56(8),4140-4145","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1093\/jac\/dkz018","volume":"74","author":"Das S.","year":"2019","unstructured":"Das S.; Garg T.; Chopra S.; Dasgupta A.; Repurposing disulfiram to target infections caused by non-tuberculous mycobacteria. J Antimicrob Chemother 2019,74(5),1317-1322","journal-title":"J Antimicrob Chemother"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"S445","DOI":"10.1093\/infdis\/jix131","volume":"216","author":"Arendrup M.C.","year":"2017","unstructured":"Arendrup M.C.; Patterson T.F.; Multidrug-resistant candida: epidemiology, molecular mechanisms, and treatment. J Infect Dis 2017,216(Suppl. 3),S445-S451","journal-title":"J Infect Dis"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3314\/jjmm.48.109","volume":"48","author":"Khan S.","year":"2007","unstructured":"Khan S.; Singhal S.; Mathur T.; Upadhyay D.J.; Rattan A.; Antifungal potential of disulfiram. Nippon Ishinkin Gakkai Zasshi 2007,48(3),109-113","journal-title":"Nippon Ishinkin Gakkai Zasshi"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"e00994","DOI":"10.1128\/AAC.00994-19","volume":"63","author":"Ortiz S.C.","year":"2019","unstructured":"Ortiz S.C.; Huang M.; Hull C.M.; Spore germination as a target for antifungal therapeutics. Antimicrob Agents Chemother 2019,63,e00994-e19","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12941-015-0090-4","volume":"14","author":"Kim K.","year":"2015","unstructured":"Kim K.; Zilbermintz L.; Martchenko M.; Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans. Ann Clin Microbiol Antimicrob 2015,14,32","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s10156-013-0639-0","volume":"19","author":"Kaneko Y.","year":"2013","unstructured":"Kaneko Y.; Fukazawa H.; Ohno H.; Miyazaki Y.; Combinatory effect of fluconazole and FDA-approved drugs against Candida albi-cans. J Infect Chemother 2013,19(6),1141-1145","journal-title":"J Infect Chemother"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"e00609","DOI":"10.1128\/AAC.00609-19","volume":"63","author":"Krajaejun T.","year":"2019","unstructured":"Krajaejun T.; Lohnoo T.; Yingyong W.; Rujirawat T.; Kumsang Y.; Jongkhajornpong P.; Theerawatanasirikul S.; Kittichotirat W.; Reamtong O.; Yolanda H.; The repurposed drug disulfiram inhibits urease and aldehyde sehydrogenase and prevents growth of the oo-mycete. Antimicrob Agents Chemother 2019,63,e00609-e00619","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.bbrc.2004.07.151","volume":"322","author":"Shukla S.","year":"2004","unstructured":"Shukla S.; Sauna Z.E.; Prasad R.; Ambudkar S.V.; Disulfiram is a potent modulator of multidrug transporter Cdr1p of Candida albicans. Biochem Biophys Res Commun 2004,322(2),520-525","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"5692","DOI":"10.1038\/s41598-017-05741-y","volume":"7","author":"Bar-Yosef H.","year":"2017","unstructured":"Bar-Yosef H.; Vivanco Gonzalez N.; Ben-Aroya S.; Kron S.J.; Kornitzer D.; Chemical inhibitors of Candida albicans hyphal morpho-genesis target endocytosis. Sci Rep 2017,7(1),5692","journal-title":"Sci Rep"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.it.2016.12.003","volume":"38","author":"Darcis G.","year":"2017","unstructured":"Darcis G.; Van Driessche B.; Van Lint C.; HIV latency: should we shock or lock? Trends Immunol 2017,38(3),217-228","journal-title":"Trends Immunol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/S0140-6736(88)90184-5","volume":"2","author":"Lang J.M.","year":"1988","unstructured":"Lang J.M.; Touraine J.L.; Trepo C.; Choutet P.; Kirstetter M.; Falkenrodt A.; Herviou L.; Livrozet J.M.; Retornaz G.; Touraine F.; Randomised, double-blind, placebo-controlled trial of ditiocarb sodium (\u2018Imuthiol\u2019) in human immunodeficiency virus infection. Lancet 1988,2(8613),702-706","journal-title":"Lancet"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1001\/jama.1991.03460120052035","volume":"265","author":"Hersh E.M.","year":"1991","unstructured":"Hersh E.M.; Brewton G.; Abrams D.; Bartlett J.; Galpin J.; Gill P.; Gorter R.; Gottlieb M.; Jonikas J.J.; Landesman S.; Ditiocarb sodi-um (diethyldithiocarbamate) therapy in patients with symptomatic HIV infection and AIDS. A randomized, double-blind, placebo-controlled, multicenter study. JAMA 1991,265(12),1538-1544","journal-title":"JAMA"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1093\/jac\/dkh292","volume":"54","author":"Siliciano J.D.","year":"2004","unstructured":"Siliciano J.D.; Siliciano R.F.; A long-term latent reservoir for HIV-1: discovery and clinical implications. J Antimicrob Chemother 2004,54(1),6-9","journal-title":"J Antimicrob Chemother"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"6060","DOI":"10.1128\/JVI.02033-10","volume":"85","author":"Xing S.","year":"2011","unstructured":"Xing S.; Bullen C.K.; Shroff N.S.; Shan L.; Yang H.C.; Manucci J.L.; Bhat S.; Zhang H.; Margolick J.B.; Quinn T.C.; Margolis D.M.; Siliciano J.D.; Siliciano R.F.; Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without induc-ing global T cell activation. J Virol 2011,85(12),6060-6064","journal-title":"J Virol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"F7","DOI":"10.1097\/QAD.0b013e3283570620","volume":"27","author":"Doyon G.","year":"2013","unstructured":"Doyon G.; Zerbato J.; Mellors J.W.; Sluis-Cremer N.; Disulfiram reactivates latent HIV-1 expression through depletion of the phospha-tase and tensin homolog. AIDS 2013,27(2),F7-F11","journal-title":"AIDS"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1097\/QAI.0000000000001958","volume":"80","author":"Kula A.","year":"2019","unstructured":"Kula A.; Delacourt N.; Bouchat S.; Darcis G.; Avettand-Fenoel V.; Verdikt R.; Corazza F.; Necsoi C.; Vanhulle C.; Bendoumou M.; Burny A.; De Wit S.; Rouzioux C.; Rohr O.; Van Lint C.; Heterogeneous HIV-1 reactivation patterns of disulfiram and combined disul-firam + romidepsin treatments. J Acquir Immune Defic Syndr 2019,80(5),605-613","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref=55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004156","volume":"10","author":"Mohammadi P.","year":"2014","unstructured":"Mohammadi P.; di Iulio J.; Mu\u00f1oz M.; Martinez R.; Bartha I.; Cavassini M.; Thorball C.; Fellay J.; Beerenwinkel N.; Ciuffi A.; Telenti A.; Dynamics of HIV latency and reactivation in a primary CD4+ T cell model. PLoS Pathog 2014,10(5)","journal-title":"PLoS Pathog"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"e520","DOI":"10.1016\/S2352-3018(15)00226-X","volume":"2","author":"Elliott J.H.","year":"2015","unstructured":"Elliott J.H.; McMahon J.H.; Chang C.C.; Lee S.A.; Hartogensis W.; Bumpus N.; Savic R.; Roney J.; Hoh R.; Solomon A.; Piatak M.; Gorelick R.J.; Lifson J.; Bacchetti P.; Deeks S.G.; Lewin S.R.; Short-term administration of disulfiram for reversal of latent HIV infec-tion: a phase 2 dose-escalation study. Lancet HIV 2015,2(12),e520-e529","journal-title":"Lancet HIV"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.antiviral.2017.12.015","volume":"150","author":"Lin M.H.","year":"2018","unstructured":"Lin M.H.; Moses D.C.; Hsieh C.H.; Cheng S.C.; Chen Y.H.; Sun C.Y.; Chou C.Y.; Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes. Antiviral Res 2018,150,155-163","journal-title":"Antiviral Res"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","volume":"582","author":"Jin Z.","year":"2020","unstructured":"Jin Z.; Du X.; Xu Y.; Deng Y.; Liu M.; Zhao Y.; Zhang B.; Li X.; Zhang L.; Peng C.; Duan Y.; Yu J.; Wang L.; Yang K.; Liu F.; Jiang R.; Yang X.; You T.; Liu X.; Yang X.; Bai F.; Liu H.; Liu X.; Guddat L.W.; Xu W.; Xiao G.; Qin C.; Shi Z.; Jiang H.; Rao Z.; Yang H.; Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature 2020,582(7811),289-293","journal-title":"Nature"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1021\/acsptsci.1c00022","volume":"4","author":"Chen T.","year":"2021","unstructured":"Chen T.; Fei C.Y.; Chen Y.P.; Sargsyan K.; Chang C.P.; Yuan H.S.; Lim C.; Synergistic inhibition of sars-cov-2 replication using disulfi-ram\/ebselen and remdesivir. ACS Pharmacol Transl Sci 2021,4(2),898-907","journal-title":"ACS Pharmacol Transl Sci"},{"key":"ref=60","unstructured":"U.S. National Institutes of Health ClinicalTrials Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04485130"},{"key":"ref=61","unstructured":"U.S. National Institutes of Health ClinicalTrials Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04594343"},{"key":"ref=62","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0259061","volume":"16","author":"Fillmore N.","year":"2021","unstructured":"Fillmore N.; Bell S.; Shen C.; Nguyen V.; La J.; Dubreuil M.; Strymish J.; Brophy M.; Mehta G.; Wu H.; Lieberman J.; Do N.; Sander C.; Disulfiram use is associated with lower risk of COVID-19: A retrospective cohort study. PLoS One 2021,16(10)","journal-title":"PLoS One"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1128\/CMR.14.1.114-128.2001","volume":"14","author":"Gardner T.B.","year":"2001","unstructured":"Gardner T.B.; Hill D.R.; Treatment of giardiasis. Clin Microbiol Rev 2001,14(1),114-128","journal-title":"Clin Microbiol Rev"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1128\/AAC.42.6.1488","volume":"42","author":"Nash T.","year":"1998","unstructured":"Nash T.; Rice W.G.; Efficacies of zinc-finger-active drugs against Giardia lamblia. Antimicrob Agents Chemother 1998,42(6),1488-1492","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"10502","DOI":"10.1074\/jbc.M114.553123","volume":"289","author":"Galkin A.","year":"2014","unstructured":"Galkin A.; Kulakova L.; Lim K.; Chen C.Z.; Zheng W.; Turko I.V.; Herzberg O.; Structural basis for inactivation of Giardia lamblia carbamate kinase by disulfiram. J Biol Chem 2014,289(15),10502-10509","journal-title":"J Biol Chem"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.ijpddr.2017.11.003","volume":"7","author":"Castillo-Villanueva A.","year":"2017","unstructured":"Castillo-Villanueva A.; Rufino-Gonz\u00e1lez Y.; M\u00e9ndez S.T.; Torres-Arroyo A.; Ponce-Macotela M.; Mart\u00ednez-Gordillo M.N.; Reyes-Vivas H.; Oria-Hern\u00e1ndez J.; Disulfiram as a novel inactivator of Giardia lamblia triosephosphate isomerase with antigiardial potential. Int J Parasitol Drugs Drug Resist 2017,7(3),425-432","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1080\/14756366.2018.1540474","volume":"34","author":"Sarwono A.E.Y.","year":"2019","unstructured":"Sarwono A.E.Y.; Mitsuhashi S.; Kabir M.H.B.; Shigetomi K.; Okada T.; Ohsaka F.; Otsuguro S.; Maenaka K.; Igarashi M.; Kato K.; Ubukata M.; Repurposing existing drugs: identification of irreversible IMPDH inhibitors by high-throughput screening. J Enzyme Inhib Med Chem 2019,34(1),171-178","journal-title":"J Enzyme Inhib Med Chem"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1093\/jac\/42.6.817","volume":"42","author":"Bouma M.J.","year":"1998","unstructured":"Bouma M.J.; Snowdon D.; Fairlamb A.H.; Ackers J.P.; Activity of disulfiram (bis(diethylthiocarbamoyl)disulphide) and ditiocarb (di-ethyldithiocarbamate) against metronidazole-sensitive and -resistant Trichomonas vaginalis and Tritrichomonas foetus. J Antimicrob Chemother 1998,42(6),817-820","journal-title":"J Antimicrob Chemother"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1136\/sextrans-2013-051032","volume":"89","author":"Goodhew E.B.","year":"2013","unstructured":"Goodhew E.B.; Secor W.E.; Drug library screening against metronidazole-sensitive and metronidazole-resistant Trichomonas vaginalis isolates. Sex Transm Infect 2013,89(6),479-484","journal-title":"Sex Transm Infect"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"5303","DOI":"10.1073\/pnas.76.10.5303","volume":"76","author":"Scheibel L.W.","year":"1979","unstructured":"Scheibel L.W.; Adler A.; Trager W.; Tetraethylthiuram disulfide (Antabuse) inhibits the human malaria parasite Plasmodium falciparum. Proc Natl Acad Sci USA 1979,76(10),5303-5307","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/S0006-2952(03)00396-4","volume":"66","author":"Deharo E.","year":"2003","unstructured":"Deharo E.; Barkan D.; Krugliak M.; Golenser J.; Ginsburg H.; Potentiation of the antimalarial action of chloroquine in rodent malaria by drugs known to reduce cellular glutathione levels. Biochem Pharmacol 2003,66(5),809-817","journal-title":"Biochem Pharmacol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1128\/CMR.19.1.111-126.2006","volume":"19","author":"Croft S.L.","year":"2006","unstructured":"Croft S.L.; Sundar S.; Fairlamb A.H.; Drug resistance in leishmaniasis. Clin Microbiol Rev 2006,19(1),111-126","journal-title":"Clin Microbiol Rev"},{"key":"ref=73","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000540","volume":"3","author":"Sharlow E.R.","year":"2009","unstructured":"Sharlow E.R.; Close D.; Shun T.; Leimgruber S.; Reed R.; Mustata G.; Wipf P.; Johnson J.; O\u2019Neil M.; Gr\u00f6gl M.; Magill A.J.; Lazo J.S.; Identification of potent chemotypes targeting Leishmania major using a high-throughput, low-stringency, computationally enhanced, small molecule screen. PLoS Negl Trop Dis 2009,3(11)","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1128\/AAC.00887-13","volume":"58","author":"Peniche A.G.","year":"2014","unstructured":"Peniche A.G.; Osorio Y.; Renslo A.R.; Frantz D.E.; Melby P.C.; Travi B.L.; Development of an ex vivo lymph node explant model for identification of novel molecules active against Leishmania major. Antimicrob Agents Chemother 2014,58(1),78-87","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"6463","DOI":"10.1128\/AAC.05131-14","volume":"59","author":"Peniche A.G.","year":"2015","unstructured":"Peniche A.G.; Renslo A.R.; Melby P.C.; Travi B.L.; Antileishmanial activity of disulfiram and thiuram disulfide analogs in an ex vivo model system is selectively enhanced by the addition of divalent metal ions. Antimicrob Agents Chemother 2015,59(10),6463-6470","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/0162-0134(95)00027-5","volume":"60","author":"Rodrigues R.R.","year":"1995","unstructured":"Rodrigues R.R.; Lane J.E.; Carter C.E.; Bogitsh B.J.; Singh P.K.; Zimmerman L.J.; Molenda J.J.; Jones M.M.; Chelating agent inhibi-tion of Trypanosoma cruzi epimastigotes in vitro. J Inorg Biochem 1995,60(4),277-288","journal-title":"J Inorg Biochem"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"263","DOI":"10.4269\/ajtmh.1996.55.263","volume":"55","author":"Lane J.E.","year":"1996","unstructured":"Lane J.E.; Ribeiro-Rodrigues R.; Suarez C.C.; Bogitsh B.J.; Jones M.M.; Singh P.K.; Carter C.E.; In vitro trypanocidal activity of tet-raethylthiuram disulfide and sodium diethylamine-N-carbodithioate on Trypanosoma cruzi. Am J Trop Med Hyg 1996,55(3),263-266","journal-title":"Am J Trop Med Hyg"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/j.1600-0773.1948.tb03350.x","volume":"4","author":"Hald J.","year":"1948","unstructured":"Hald J.; Jacobsen E.; The sensitizing effect of tetraethylthiuramdisulphide (Antabuse) to ethylalcohol. Act Pharmacol 1948,4,285-296","journal-title":"Act Pharmacol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"508","DOI":"10.4269\/ajtmh.1979.28.508","volume":"28","author":"Seed J.L.","year":"1979","unstructured":"Seed J.L.; Pratt M.C.; Bennett J.L.; The effects of chronic disulfiram treatment on mice infected with Schistosoma mansoni. Am J Trop Med Hyg 1979,28(3),508-514","journal-title":"Am J Trop Med Hyg"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"938","DOI":"10.2307\/3284293","volume":"83","author":"Hill D.E.","year":"1997","unstructured":"Hill D.E.; Fetterer R.H.; The effect of disulfiram on egg shell formation in adult Trichuris muris. J Parasitol 1997,83(5),938-942","journal-title":"J Parasitol"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.it.2017.01.003","volume":"38","author":"Aglietti R.A.","year":"2017","unstructured":"Aglietti R.A.; Dueber E.C.; Recent insights into the molecular mechanisms underlying pyroptosis and gasdermin family functions. Trends Immunol 2017,38(4),261-271","journal-title":"Trends Immunol"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1039\/C9MD00059C","volume":"10","author":"Pandeya A.","year":"2019","unstructured":"Pandeya A.; Li L.; Li Z.; Wei Y.; Gasdermin D.; Gasdermin D.; GSDMD) as a new target for the treatment of infection. MedChemComm 2019,10(5),660-667","journal-title":"MedChemComm"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/s41590-020-0669-6","volume":"21","author":"Hu J.J.","year":"2020","unstructured":"Hu J.J.; Liu X.; Xia S.; Zhang Z.; Zhang Y.; Zhao J.; Ruan J.; Luo X.; Lou X.; Bai Y.; Wang J.; Hollingsworth L.R.; Magupalli V.G.; Zhao L.; Luo H.R.; Kim J.; Lieberman J.; Wu H.; FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation. Nat Immunol 2020,21(7),736-745","journal-title":"Nat Immunol"}],"container-title":["Anti-Infective Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/2211352520666220104104747","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/199856\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/2211352520666220104104747","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T17:09:46Z","timestamp":1691600986000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/199856\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":83,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/2211352520666220104104747","relation":{},"ISSN":["2211-3525"],"issn-type":[{"value":"2211-3525","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-07-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-01","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e040122199856"}}